Explanipedia

Revised ISHAM-ABPA working group clinical practice guidelines for diagnosing, classifying and treating allergic bronchopulmonary aspergillosis/mycoses Open

Ritesh Agarwal, Inderpaul Singh Sehgal, Valliappan Muthu, David W. Denning, Arunaloke Chakrabarti , et al. · 2024

Background The International Society for Human and Animal Mycology (ISHAM) working group proposed recommendations for managing allergic bronchopulmonary aspergillosis (ABPA) a decade ago. There is a need to update these recommendations due…

Correction: Moss, R.B. Severe Fungal Asthma: A Role for Biologics and Inhaled Antifungals. J. Fungi 2023, 9, 85 Open

Richard B. Moss · 2023

In the original publication [...]

Evaluation of Acebilustat, a Selective Inhibitor of Leukotriene B4 Biosynthesis, for Treatment of Outpatients With Mild-Moderate Coronavirus Disease 2019: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial Open

Joseph E. Levitt, Haley Hedlin, Sophie Duong, Di Lu, Justin Lee , et al. · 2023

Background The vast majority of coronavirus disease 2019 (COVID-19) disease occurs in outpatients where treatment is limited to antivirals for high-risk subgroups. Acebilustat, a leukotriene B4 inhibitor, has potential to reduce inflammati…

Severe Fungal Asthma: A Role for Biologics and Inhaled Antifungals Open

Richard B. Moss · 2023

Allergic asthma has traditionally been treated with inhaled and systemic glucocorticosteroids. A continuum of allergic fungal airways disease associated with Aspergillus fumigatus colonization and/or atopic immune responses that encompasse…

Rate of Lung Function Decline in People with Cystic Fibrosis Having a Residual Function Gene Mutation Open

Gregory S. Sawicki, Michael W. Konstan, Edward F. McKone, Richard B. Moss, Barry Lubarsky , et al. · 2022

Progressive lung function decline was observed in people with F/RF genotypes across all assessed age groups, reinforcing the importance of early intervention and clinical monitoring to preserve lung function in all people with CF.

Clinician variability in the diagnosis and treatment of aspergillus fumigatus-related conditions in cystic fibrosis: An international survey Open

Gina Hong, Sameer Desai, Richard B. Moss, Patience Eschenhagen, Bradley S. Quon , et al. · 2021

Potential Novel Variant Nephronophthisis with Pediatric End-Stage Renal Disease and Bronchiectasis Open

I. Lee, Richard B. Moss · 2021

Diagnosing allergic bronchopulmonary aspergillosis/mycosis: Return to lost horizons Open

Richard B. Moss · 2021

Long-Term Ivacaftor in People Aged 6 Years and Older with Cystic Fibrosis with Ivacaftor-Responsive Mutations Open

Joseph M. Pilewski, K. De Boeck, Jerry A. Nick, Simon Tian, Cynthia DeSouza , et al. · 2020

Introduction Mutations in the cystic fibrosis transmembrane conductance regulator gene ( CFTR ) affect the quantity and/or function of CFTR protein reaching the cell surface. Ivacaftor, a CFTR potentiator that enhances chloride transport, …

Mucosal humoral immunity in cystic fibrosis - a tangled web of failed proteostasis, infection and adaptive immunity Open

Richard B. Moss · 2020

The central role of chronic endobronchial infection with Pseudomonas aeruginosa (Pa) in the pathophysiology of cystic fibrosis (CF) has long focused on defects in compartmental host defense as well as pathogen adaptability [[1]Malhotra S. …

P107 ECFS/CFF global survey on diagnosis and treatment of Aspergillus fumigatus-related conditions Open

Gina Hong, Richard B. Moss, Bonnie Marshall, Bradley S. Quon, Patience Eschenhagen , et al. · 2020

Early Aspergillosis in Cystic Fibrosis and Air Trapping: Guilt by Association? Open

Dave P. Nichols, Richard B. Moss · 2020

Sweat rate analysis of ivacaftor potentiation of CFTR in non-CF adults Open

Jeeyeon Kim, Miesha Farahmand, Colleen Dunn, Carlos Milla, Rina I. Horii , et al. · 2018

Issue Information ‐ TOC Open

Michael Greenberg, Karen Lowrie, Igor Linkov, Cate Fox‐Lent, Laura Read , et al. · 2018

The myriad challenges of respiratory fungal infection in cystic fibrosis Open

Michael C. Tracy, Richard B. Moss · 2018

Fungal infection in cystic fibrosis (CF) is a recognized challenge, with many areas requiring further investigation. Consensus definitions exist for allergic bronchopulmonary aspergillus in CF, but the full scope of clinically relevant non…

Resistin is elevated in cystic fibrosis sputum and correlates negatively with lung function Open

Osric Forrest, Daniel M. Chopyk, Yaël Gernez, Milton R. Brown, C. Conrad , et al. · 2018

Anaphylaxis: getting to the point (and price) of diagnosis and treatment Open

Richard B. Moss · 2018

Ronald B MossAdamis Pharmaceuticals Corporation, San Diego, CA, USAAnaphylaxis was first described by Charles Richet and Paul Portier in 1901 as an immune reaction that is the opposite of immune protection resulting from vaccination.1 Anap…

Cystic fibrosis transmembrane conductance regulator modulators: precision medicine in cystic fibrosis Open

Elizabeth B. Burgener, Richard B. Moss · 2018

Purpose of review The aim of this study was to describe the newest development in cystic fibrosis (CF) care, CF transmembrane conductance regulator (CFTR) modulator therapies. Recent findings Phase II results showing CFTR modulator triple …

Lung function decline is delayed but not decreased in patients with cystic fibrosis and the R117H gene mutation Open

Jeffrey S. Wagener, Stefanie J. Millar, Nicole Mayer-Hamblett, Gregory S. Sawicki, Edward F. McKone , et al. · 2017

54 Relationship between rate of percent predicted FEV1 (ppFEV1) decline and baseline and acute change in ppFEV1 in patients (pts) with cystic fibrosis (CF) treated with lumacaftor/ivacaftor (LUM/IVA) Open

Michael W. Konstan, E.F. McKone, Richard B. Moss, Barry Lubarsky, Jaime Rubin , et al. · 2017

EPS4.3 Differential sensitivity of outcome measures that assess progression of mild CF lung disease in school age children Open

Tamira Robinson, Marina Goris, Richard B. Moss, Liming Tian, Piseth Kan , et al. · 2017

The magnitude of ivacaftor effects on fluid secretion via R117H-CFTR channels: Human in vivo measurements Open

Jessica E. Char, Colleen Dunn, Zoe Davies, Carlos Milla, Richard B. Moss , et al. · 2017

We optically measured effects of orally available ivacaftor (Kalydeco®) on sweat rates of identified glands in 3 R117H subjects, each having a unique set of additional mutations, and compared them with 5 healthy control subjects tested con…

Allergic Bronchopulmonary Aspergillosis Open

Michael C. Tracy, Caroline U. A. Okorie, Elizabeth Price Foley, Richard B. Moss · 2016

Allergic bronchopulmonary aspergillosis (ABPA), a progressive fungal allergic lung disease, is a common complication of asthma or cystic fibrosis. Although ABPA has been recognized since the 1950s, recent research has underscored the impor…

WS04.2 Improvement in inflammatory biomarkers in patients (pts) with cystic fibrosis (CF) homozygous for the F508del-CFTR mutation treated with lumacaftor (LUM) and ivacaftor (IVA) Open

J. C. Sullivan, Frank J. Accurso, Gautham Marigowda, Jack Beusmans, David Geho , et al. · 2016

Basophil activation test determination of CD63 combined with CD203c is not superior to CD203c alone in identifying allergic bronchopulmonary aspergillosis in cystic fibrosis Open

Yaël Gernez, Jeffrey Waters, Rabindra Tirouvanziam, Leonore A. Herzenberg, Richard B. Moss · 2016

Earth Mover’s Distance (EMD): A True Metric for Comparing Biomarker Expression Levels in Cell Populations Open

Darya Orlova, Noah Zimmerman, Stephen Meehan, Connor Meehan, Jeffrey Waters , et al. · 2016

Changes in the frequencies of cell subsets that (co)express characteristic biomarkers, or levels of the biomarkers on the subsets, are widely used as indices of drug response, disease prognosis, stem cell reconstitution, etc. However, alth…

Modulatory Effects of Aspergillus Colonization and Abpa on Blood and Sputum Granulocytes in CF Open

Yaël Gernez, Jeffrey Waters, Colleen Dunn, Zoe Davies, Cassie Everson , et al. · 2016

Treating allergic bronchopulmonary aspergillosis: the way forward Open

Richard B. Moss · 2016

Allergic bronchopulmonary mycoses are an endotype of allergic lung disease, similar to but more severe than uncomplicated asthma, caused by a Th2-dominated immune response and a bronchocentric granulocytic inflammation provoked by endobron…

Effect of Media Modified To Mimic Cystic Fibrosis Sputum on the Susceptibility of Aspergillus fumigatus, and the Frequency of Resistance at One Center Open

David A. Stevens, Richard B. Moss, Cathy Hernandez, Karl V. Clemons, Marife Martinez · 2016

Studies of cystic fibrosis (CF) patient exacerbations attributed to Pseudomonas aeruginosa infection have indicated a lack of correlation of outcome with in vitro susceptibility results. One explanation is that the media used for testing d…

DAS181 Treatment of Severe Parainfluenza Virus 3 Pneumonia in Allogeneic Hematopoietic Stem Cell Transplant Recipients Requiring Mechanical Ventilation Open

Binod Dhakal, Anita D’Souza, Marcelo C. Pasquini, Wael Saber, Timothy S. Fenske , et al. · 2016

Parainfluenza virus (PIV) may cause life-threatening pneumonia in allogeneic hematopoietic stem cell transplant (HSCT) recipients. Currently, there are no proven effective therapies. We report the use of inhaled DAS181, a novel sialidase f…

Richard B. Moss YOU? Author Swipe